MULTIPLE MYELOMA (MM) Clinical Trial
Official title:
A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as Pre Transplant INDUCTION and Post Transplant Consolidation or CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (CRd) as Pre Transplant INDUCTION and Post Transplant Consolidation or Continuous Treatment With CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (12 Cycles) Without Transplant, All Followed by MAINTENANCE With LENALIDOMIDE (R) Versus LENALIDOMIDE AND CARFILZOMIB (CR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT
This study will evaluate the safety and the efficacy of carfilzomib combined with cyclophosphamide and dexamethasone (CCyd) or lenalidomide and dexamethasone (CRd) followed by autologous transplantation ASCT or 12 cycles of carfilzomib combined with dexamethasone and lenalidomide for patients eligible for ASCT with newly diagnosed multiple myeloma. As a secondary endpoint this study will evaluate the best maintenance treatment between lenalidomide and lenalidomide combined with carfilzomib. Four hundred seventy-seven patients, males and females aged > 18 years, enrolled in several sites, will take part in this study. The duration of the study is approximately 5 years.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02265731 -
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05442580 -
CART-38 in Adult AML and MM Patients
|
Phase 1 | |
| Terminated |
NCT04178902 -
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02920697 -
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05908409 -
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04702425 -
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
|
Phase 1 | |
| Completed |
NCT00710528 -
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT04721002 -
Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
|
||
| Active, not recruiting |
NCT02240537 -
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
|
Phase 1 | |
| Completed |
NCT02211014 -
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT04649073 -
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04123418 -
A Study of WVT078 in Patients With Multiple Myeloma (MM)
|
Phase 1 | |
| Recruiting |
NCT03018405 -
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
|
Phase 1/Phase 2 | |
| Terminated |
NCT01663766 -
Phase I Study of Milatuzumab for Graft Versus Host Disease
|
Phase 1 | |
| Completed |
NCT01919086 -
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
|
Phase 2 | |
| Withdrawn |
NCT05513612 -
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
|
Phase 1 | |
| Completed |
NCT01413568 -
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00889798 -
Tumor Registry of Lymphatic Neoplasia
|